Transurethral ultrasound ablation (TULSA) for benign prostatic obstruction: 12 months clinical outcomes
Anttinen et al, AUA 2023 Annual Meeting (abstract MP76-10), The Journal of Urology (2023)
MRI-guided transurethral ultrasound ablation for BPH: 12-month clinical outcomes of a phase I study
Viitala et al, British Journal of Urology International (2021)
Radio-Recurrent Localized Prostate Cancer: Phase I Study of Salvage TULSA (n=34)
Salvage transurethral ultrasound ablation (TULSA) for localized radio-recurrent prostate cancer: 12-month safety and oncological outcomes
Anttinen et al, EAU 2023 Annual Congress (abstract A0965), The Journal of Urology (2023)
Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers
Mäkelä et al, Acta Radiologica (2022)
Salvage MRI-guided TULSA for localized radio-recurrent prostate cancer: 12-month functional and oncological results
Anttinen et al, European Urology Open Science (2020)
Palliation of Symptomatic Locally Advanced Prostate Cancer: Phase I Study of Palliative TULSA (n=10)
Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer
Anttinen et al, Scandinavian Journal of Urology (2020)
Customized Ablation Plans in Clinical Trials (n=60)
12-month clinical outcomes of MRI-guided transurethral ultrasound ablation for localized prostate cancer
Yli-Pietilä et al, EAU 2023 Annual Congress (abstract A0996), European Urology (2023)
Randomized Controlled Trials (RCT)
Comparison of postoperative complications between focal ablation and radical prostatectomy for intermediate-risk prostate cancer: the FARP randomized control trial
Baco et al, AUA 2023 Annual Meeting (abstract MP73-15), The Journal of Urology (2023)
Clinical Consultation Guide
Optimal strategies for managing prostate-specific antigen recurrence after primary radiotherapy in prostate cancer: The Finnish Perspective
Seikkula et al, European Urology Focus (2023)
CAUTION: Products shown may not be approved for sale in all jurisdictions. Rx only device.
Contact us at info@profoundmedical.com for more information regarding the regulatory status of the device.
106734B